摘要
阿尔茨海默病(AD)是与认知功能障碍相关的不可逆的神经变性疾病。本病发病率在全国范围内有上升趋势,给医疗保健基金带来了强劲冲击。没有有效治疗方法的事实使得该病症更为严重。目前,作用于乙酰胆碱酯酶(多奈哌齐,利斯的明和加兰他敏或离子型谷氨酸NMDA受体(memanitine))可以抑制AD表现形式。与药物对症影响相反,抗淀粉样蛋白斑或神经原纤维缠结和它们的前体β淀粉样蛋白和tau蛋白的疫苗接种是更合适的。人们在这个问题上已进行了大量研究。不幸的是,有前景的疫苗,如AN 1792,因为像脑膜脑炎的不良反应的在临床试验就被停止了。特定于淀粉样蛋白斑的单克隆抗体,bapineuzumab,虽然最接近实用性能,但也在临床试验中也被停止。该综述总结关于AD的事实,AD疫苗接种的机会,和限制了疫苗接种的障碍包括为什么最近的试验失败的原因。
关键词: 阿尔茨海默病,免疫,淀粉样蛋白斑,神经原纤维缠结,tau蛋白,β淀粉样蛋白,神经胶质细胞。
Current Medicinal Chemistry
Title:Vaccination to Alzheimer Disease. Is it a Promising Tool or a Blind Way?
Volume: 23 Issue: 14
Author(s): Miroslav Pohanka
Affiliation:
关键词: 阿尔茨海默病,免疫,淀粉样蛋白斑,神经原纤维缠结,tau蛋白,β淀粉样蛋白,神经胶质细胞。
摘要: Alzheimer disease (AD) is an irreversible neurodegenerative disorder associated with cognitive dysfunction. The disease incidence has growing tendency worldwide with strong impact on healthcare funds. The fact that there is no effective therapy makes the disorder more serious. Currently, AD manifestation can be suppressed by having impact on enzyme acetylcholinesterase: donepezil, rivastigmine, and galantamine or ionotropic glutamate NMDA receptor ( memanitine). Contrary to the drugs effecting symptomatically, vaccination against amyloid plaques or neurofibrillary tangles and their precursors amyloid beta and hyperphosphorylated tau are expected to be more suitable. Huge numbers of works have been done on the issue. Unfortunately, the promising vaccines like the AN 1792 were halted during clinical trials because of adverse effects like meningoencephalitis. Monoclonal antibody specific to amyloid plaques, Bapineuzumab, was closest to the practical performance but the clinical trials were also stopped. The review summarizes facts about AD, opportunities in AD vaccination, and obstacles that limit the vaccination including reasons why the recent trials have fallen.
Export Options
About this article
Cite this article as:
Miroslav Pohanka , Vaccination to Alzheimer Disease. Is it a Promising Tool or a Blind Way?, Current Medicinal Chemistry 2016; 23 (14) . https://dx.doi.org/10.2174/0929867323666160418114733
DOI https://dx.doi.org/10.2174/0929867323666160418114733 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
DL-3-n-Butylphthalide, an Anti-Oxidant Agent, Prevents Neurological Deficits and Cerebral Injury Following Stroke per Functional Analysis, Magnetic Resonance Imaging and Histological Assessment
Current Neurovascular Research Critical Issues in Delivery of RNAi Therapeutics In Vivo
Current Pharmaceutical Biotechnology The Expanding Universe of Neurotrophic Factors: Therapeutic Potential in Aging and Age-Associated Disorders
Current Pharmaceutical Design Early Features in Frontotemporal Dementia
Current Alzheimer Research Cation-Responsive MRI Contrast Agents Based on Gadolinium(III)
Current Inorganic Chemistry (Discontinued) Genetic Variants and Oxidative Stress in Alzheimer’s Disease
Current Alzheimer Research A New Interpretative Paradigm for Conformational Protein Diseases
Current Protein & Peptide Science Subcellular Injuries in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets The Positive Synergism of CPT and MK-801 in Behavioral Tests and in Reduction of Environmental Stress and Redox Signaling Changes in Mice Cerebral Cortex
CNS & Neurological Disorders - Drug Targets Effects of the Novel Non-Peptidyl Low Molecular Weight Radical Scavenger IAC in Different Models of Inflammation: A New Perspective in Anti-Inflammatory Therapy
Current Medicinal Chemistry RNA Interference (RNAi) Patents and Human Health Related Applications of RNAi
Recent Patents on DNA & Gene Sequences Meet Our Editor-in-Chief
CNS & Neurological Disorders - Drug Targets Ferulic Acid and Alzheimer’s Disease: Promises and Pitfalls
Mini-Reviews in Medicinal Chemistry The Role of Minocycline in Ischemia-Reperfusion Injury: A Comprehensive Review of an Old Drug with New Implications
Recent Patents on Cardiovascular Drug Discovery Biological Function and Medicinal Research Significance of G-Quadruplex Interactive Proteins
Current Topics in Medicinal Chemistry Permeating the Blood Brain Barrier and Abrogating the Inflammation in Stroke: Implications for Stroke Therapy
Current Pharmaceutical Design Melatonin and Synthetic Melatoninergic Agonists in Psychiatric and Age-associated Disorders: Successful and Unsuccessful Approaches
Current Pharmaceutical Design Neuronal Death in Amyotrophic Lateral Sclerosis (ALS): What Can We Learn from Genetics?
CNS & Neurological Disorders - Drug Targets Amyloidophilic Compounds for Prion Diseases
Infectious Disorders - Drug Targets Peptide Inhibitors Targeting Protein Kinases
Current Pharmaceutical Design